BOSTON and MONTREAL, Nov. 29, 2023 /CNW/ - enGene Holdings Inc. ("enGene,") (NASDAQ: ENGN) (NASDAQ: ENGNW), a clinical-stage genetic medicines company whose lead program is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the appointment of Ryan Daws as Chief Financial Officer and Head of Business Development.
Read more at newswire.cahello world
Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.
